258 related articles for article (PubMed ID: 30464041)
21. Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs.
Wächter S; Wunderlich A; Greene BH; Roth S; Elxnat M; Fellinger SA; Verburg FA; Luster M; Bartsch DK; Di Fazio P
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018229
[TBL] [Abstract][Full Text] [Related]
22. Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors.
Smith VE; Sharma N; Watkins RJ; Read ML; Ryan GA; Kwan PP; Martin A; Watkinson JC; Boelaert K; Franklyn JA; McCabe CJ
J Clin Endocrinol Metab; 2013 Jul; 98(7):2876-86. PubMed ID: 23678037
[TBL] [Abstract][Full Text] [Related]
23. Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
Cheng W; Liu R; Zhu G; Wang H; Xing M
J Clin Endocrinol Metab; 2016 Mar; 101(3):962-71. PubMed ID: 26751190
[TBL] [Abstract][Full Text] [Related]
24. A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERRγ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer.
Singh TD; Song J; Kim J; Chin J; Ji HD; Lee JE; Lee SB; Yoon H; Yu JH; Kim SK; Yoon GS; Hwang H; Lee HW; Oh JM; Lee SW; Lee J; Choi HS; Na SY; Choi WI; Park YJ; Song YS; Kim YA; Lee IK; Cho SJ; Jeon YH
Clin Cancer Res; 2019 Aug; 25(16):5069-5081. PubMed ID: 31010838
[TBL] [Abstract][Full Text] [Related]
25. Retinoic acid and tributyrin induce in-vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma.
Zhang M; Guo R; Xu H; Zhang M; Li B
Nucl Med Commun; 2011 Jul; 32(7):605-10. PubMed ID: 21471848
[TBL] [Abstract][Full Text] [Related]
26. Thyroid Follicular Cell Loss of Differentiation Induced by MicroRNA miR-17-92 Cluster Is Attenuated by CRISPR/Cas9n Gene Silencing in Anaplastic Thyroid Cancer.
Fuziwara CS; Saito KC; Kimura ET
Thyroid; 2020 Jan; 30(1):81-94. PubMed ID: 31578932
[No Abstract] [Full Text] [Related]
27. Combined MEK and Pi3'-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo.
ElMokh O; Ruffieux-Daidié D; Roelli MA; Stooss A; Phillips WA; Gertsch J; Dettmer MS; Charles RP
Oncotarget; 2017 Apr; 8(15):24604-24620. PubMed ID: 28445948
[TBL] [Abstract][Full Text] [Related]
28. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
[No Abstract] [Full Text] [Related]
29. Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.
Liu Z; Xing M
PLoS One; 2012; 7(2):e31729. PubMed ID: 22359623
[TBL] [Abstract][Full Text] [Related]
30. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
31. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
32. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
33. PIK3CA
Roelli MA; Ruffieux-Daidié D; Stooss A; ElMokh O; Phillips WA; Dettmer MS; Charles RP
Oncotarget; 2017 Nov; 8(61):103207-103222. PubMed ID: 29262556
[TBL] [Abstract][Full Text] [Related]
34. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line.
Hegedűs L; Rittler D; Garay T; Stockhammer P; Kovács I; Döme B; Theurer S; Hager T; Herold T; Kalbourtzis S; Bankfalvi A; Schmid KW; Führer D; Aigner C; Hegedűs B
Pathol Oncol Res; 2020 Oct; 26(4):2523-2535. PubMed ID: 32591993
[TBL] [Abstract][Full Text] [Related]
35. REGγ ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radio-therapeutic response by regulating the Smad7-TGF-β pathway.
Jiao C; Li L; Zhang P; Zhang L; Li K; Fang R; Yuan L; Shi K; Pan L; Guo Q; Gao X; Chen G; Xu S; Wang Q; Zuo D; Wu W; Qiao S; Wang X; Moses R; Xiao J; Li L; Dang Y; Li X
Cell Death Differ; 2020 Feb; 27(2):497-508. PubMed ID: 31243343
[TBL] [Abstract][Full Text] [Related]
36. Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer.
Kim J; Song J; Ji HD; Yoo EK; Lee JE; Lee SB; Oh JM; Lee S; Hwang JS; Yoon H; Kim DS; Lee SJ; Jeong M; Lee S; Kim KH; Choi HS; Lee SW; Park KG; Lee IK; Kim SH; Hwang H; Jeon YH; Chin J; Cho SJ
J Med Chem; 2019 Feb; 62(4):1837-1858. PubMed ID: 30657313
[TBL] [Abstract][Full Text] [Related]
37. LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway.
Sui X; Sui Y; Wang Y
Mol Med Rep; 2018 Jun; 17(6):7521-7528. PubMed ID: 29620212
[TBL] [Abstract][Full Text] [Related]
38. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
Rothenberg SM; McFadden DG; Palmer EL; Daniels GH; Wirth LJ
Clin Cancer Res; 2015 Mar; 21(5):1028-35. PubMed ID: 25549723
[TBL] [Abstract][Full Text] [Related]
39. Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells.
Zhang H; Chen D
Thyroid Res; 2018; 11():13. PubMed ID: 30337961
[TBL] [Abstract][Full Text] [Related]
40. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
